Investors target Capricor Therapeutics in securities class action

The complaint centers on the company’s submission of a Biologics License Application for Deramiocel, which allegedly relied on modified statistical analysis plans that lacked regulatory backing. Plaintiffs contend that these undisclosed changes rendered the firm's public statements materially misleading throughout the specified class period. Investors who suffered financial losses are now being scouted by the DJS Law Group to serve as lead plaintiffs in the proceedings.

Those seeking to participate in the recovery effort must act before the September 28, 2026, deadline. While the DJS Law Group is organizing the action, shareholders are not required to be appointed as lead plaintiffs to receive a potential share of any eventual settlement. The firm, led by David J. Schwartz, specializes in corporate governance and securities litigation, representing institutional clients in complex recovery matters.